To the Editor:

Currently, coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2, is a global health threat that has resulted in more than 300,000 deaths.[@bib0001] Severe acute respiratory syndrome coronavirus 2 primarily targets the pulmonary system and causes hypoxemic respiratory failure and acute respiratory distress syndrome (ARDS). Pneumomediastinum is a well-known life-threatening complication related to the use of mechanical ventilation, especially in ARDS patients. However, publications highlighting the characteristics and outcomes of COVID-19 patients who develop pneumomediastinum after intubation and mechanical ventilation are very limited. Herein, we present our institution\'s experience with 4 patients ([Table 1](#tbl0001){ref-type="table"} ). The median age of the patients was 56 years (range 41-74 y). Two were male, and 2 were female. All patients had significant risk factors for developing severe COVID-19, including comorbidities, obesity, and the elevation of inflammatory markers. None was a smoker or had any underlying lung diseases. All patients were intubated using direct laryngoscopy, due to acute hypoxemic respiratory failure from COVID-19 pneumonia. Assist volume- control ventilation was implemented in all patients. The positive end-expiratory pressure (PEEP) values and tidal volume before the patients developed pneumomediastinum ranged from 16- to- 20 cmH~2~O and 350- to- 520 mL, respectively. One patient underwent prone intervention for 6 days on and off. The diagnosis of pneumomediastinum was confirmed by chest x-ray ([Fig 1](#fig0001){ref-type="fig"} ). Due to their persistent hypoxemia from severe ARDS, we could not decrease the ventilator settings of any of the patients after they had developed pneumomediastinum. All patients ultimately died due to septic shock and multiorgan failure from severe COVID-19. We did not perform autopsies.Table 1Patient characteristics and hospital coursesTable 1:Case1234Age/ Sex74/ female48/ female41/ male64/ maleComorbiditiesHTN, DM, HLDObesity (BMI 47)Obesity (BMI 35)Obesity (BMI 34)Smoking statusNon-smokerNon-smokerNon-smokerNon-smokerPresenting symptomsFever, cough, diarrhea, vomitingDyspnea, coughDyspnea, cough, feverDyspnea, fever, cough, diarrhea, vomitingInflammatory markersCRP 16, DD 303, IL6 75CRP 35, DD 1084, IL6 159CRP 7, DD 866, IL6 10CRP 20, DD 3009COVID-19 treatmentHydroxychloroquine, IL6 inhibitor trialHydroxychloroquineHydroxychloroquineHydroxychloroquine, convalescent plasmaDay of intubationD 1D 0D 4D 2ETT size7.57 (2 attempts)7.58Highest PEEP16201518Highest Tidal Volume350350520400Prone interventionNoNoNoYesDay from intubation13426CXRMassive pneumomediastinum and subcutaneous emphysemaRight-sided tension pneumothorax, pneumomediastinumSmall left pneumothorax, pneumomediastinum, marked subcutaneous emphysemaLarge right pneumothorax (70%)SeveritySevereSevereMildSevereManagementLeft intrapleural chest drainNeedle decompression, Right intrapleural chest drainLeft intrapleural chest drainNeedle decompression, Right intrapleural chest drainOutcomeDeath (LOS 17 days)\
Death (LOS 6 days)\
Death (LOS 30 days)\
Death (LOS 10 days)\
[^1]Figure 1CXR of the patientsFigure 1:

We searched the Medline database for pneumomediastinum in mechanically ventilated COVID-19 patients and discovered 1 previously reported case series from the United Kingdom.[@bib0002] Wali et al. described 5 COVID-19 patients who developed pneumomediastinum after tracheal intubation and mechanical ventilation and proposed that the pneumomediastinum was at least partly due to large-bore tracheal tubes (initially used size 9 in all patients) leading to tracheobronchial injury. However, our patients were intubated with a smaller size of tracheal tubes (median 7.5, ranges 7-8). We hypothesized that the primary mechanism of pneumomediastinum in these patients was barotrauma, as evident by the high requirement of PEEP in all patients. The positive correlations of high PEEP values, barotrauma, and the risks of developing pneumomediastinum are well-recognized.[@bib0003] None of our patients or those in the Wali et al. reported had underlying lung pathology. None of our patients had ever smoked. The lack of preexisting pulmonary abnormalities may support the hypothesis that the destruction of alveoli from cytokine storm in patients with severe COVID-19 is a significant predisposing factor for the development of barotrauma and pneumomediastinum. We also found substantially higher inflammatory markers in all patients, validating the occurrence of the cytokine storm. However, whether immunosuppressive agents will help in decreasing the destruction of alveoli and the risks of developing pneumomediastinum needs to be determined.

Prone positioning has shown proven benefits in patients with ARDS.[@bib0004] ^,^ [@bib0005] Recent evidence also suggested that prone positioning improves oxygenation in nonmechanically ventilated COVID-19 patients.[@bib0006] In contrast, the risks and complications of prone intervention, especially in COVID-19 patients, are not well-elucidated. From our institution\'s experience, prone positioning may lead to an increased incidence of tracheal tube cuff leakage, tracheal tube dislodgement, and a decrease in blood pressure. In addition, repositioning intervention may cause tracheobronchial injury and pneumomediastinum in intubated patients. Our 4th patientand 1 patient in the Wali et al. case series developed pneumomediastinum after prone positioning. Studies to determine the risks related to prone intervention will be worthwhile.

Adjustment of mechanical ventilation, management of lung injury and barotrauma, and treatment of pneumomediastinum in invasively ventilated COVID-19 patients, pose great challenges to all relevant health-care professionals. Studies to explore the respiratory pathophysiology and possible treatment interventions in invasively ventilated COVID-19 patients are needed urgently to solve these issues.
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[^1]: Endotracheal tube (ETT), positive end-expiratory pressure (PEEP), Chest x-ray (CXR), C-reactive protein (CRP (mg/dl), normal \<0.4 mg/dl), D-dimer (DD (ng/ml) normal \< 230 ng/ml), interleukin-6 (IL6 (pg/mL), normal \< 15.5 pg/mL), length of stay (LOS)
